 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 January 1995 | Volume 122 Issue 2 | Pages 81-89
Objective: To assess the safety and efficacy of minocycline in the treatment of rheumatoid arthritis.
Design: A double-blind, randomized, multicenter, 48-week trial of oral minocycline (200 mg/d) or placebo.
Setting: 6 clinical centers in the United States.
Patients: 219 adults with active rheumatoid arthritis who had previous limited treatment with disease-modifying drugs.
Measurements: As the primary outcomes, 60 diarthrodial joints were examined for tenderness, and 58 joints were examined for swelling (hips excluded). Grip strength, evaluator's global assessment, morning stiffness, Modified Health Assessment Questionnaire, patient's global assessment, hematocrit, erythrocyte sedimentation rate, platelet count, and IgM rheumatoid factor levels were also assessed; radiographs of both hands and wrists were taken.
Results: 109 and 110 patients were randomly assigned to receive minocycline and placebo, respectively. At entry, demographic, clinical, and laboratory measurements were similar in both groups. Most patients had mild to moderate disease activity and some evidence of destructive disease. At the week 48 visit, 79% of the minocycline group and 78% of the placebo group continued to receive the study medication. At 48 weeks, more patients in the minocycline group than in the placebo group showed improvement in joint swelling (54% and 39%) and joint tenderness (56% and 41%) (P < 0.023 for both comparisons). The minocycline group also showed greater improvement in hematocrit, erythrocyte sedimentation rate, platelet count, and IgM rheumatoid factor levels (all P values < 0.001), and more patients receiving minocycline had laboratory values within normal ranges at 48 weeks. For the remaining outcomes, P values ranged from 0.04 to 0.76, all greater than the critical value of 0.005 (Bonferroni adjustment for multiple comparisons). The frequency of reported side effects was similar in both groups, and no serious toxicity occurred.
Conclusions: Minocycline was safe and effective for patients with mild to moderate rheumatoid arthritis. Its mechanisms of action remain to be determined.
For current author affiliations, see end of text.
*For members of the MIRA Trial Group, see the Appendix. For current author affiliations, see end of text.
Author and Article Information
From the Henry Ford Health Sciences Center, Detroit, Michigan; the University of Alabama at Birmingham; National Institutes of Health, Bethesda, Maryland; Beth Israel Hospital, Boston, Massachusetts; the State University of New York at Brooklyn; the University of Utah Medical Center, Salt Lake City, Utah; and the University of Vermont, Burlington, Vermont.
ARTICLE
Minocycline in Rheumatoid Arthritis: A 48-Week, Double-Blind, Placebo-Controlled Trial
Deceased.
For the MIRA Trial Group*
Requests for Reprints: The MIRA Trial Group, c/o Stephen P. Heyse, MD, Office of Disease Prevention, Epidemiology, and Clinical Applications, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Natcher Building, Room 5AS-53, 45 Center Drive, MSC 6500, Bethesda, MD 20892-6500.
Acknowledgments: The authors thank the physicians who referred their patients to the clinical centers, the clinic coordinators, the patients who participated in the study, and Helene Boldarini and Ella Henderson for secretarial assistance.
Grant Support: By research contracts from the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases (contracts N01-AR-1-2202, N01-AR-1-2203, N01-AR-1-2205, N01-AR-1-2207, N01-AR-1-2206, N01-AR-2-2210, and N01-AR-2-2205). Study medication and placebo were provided by Lederle Laboratories, a Division of Cyanamid, Inc., Pearl River, New York.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  D. J. J. Park, J. J. Woog, J. S. Pulido, and J. D. Cameron Minocycline for the Treatment of Ocular and Ocular Adnexal Sarcoidosis Arch Ophthalmol, May 1, 2007; 125(5): 705 - 709. [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Jo, M. H. Rosner, and M. D. Okusa Pharmacologic Treatment of Acute Kidney Injury: Why Drugs Haven't Worked and What Is on the Horizon Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 356 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gaffo, K. G. Saag, and J. R. Curtis Treatment of rheumatoid arthritis Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2451 - 2465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.J. Tredwin, C. Scully, and J.-V. Bagan-Sebastian Drug-induced Disorders of Teeth J. Dent. Res., July 1, 2005; 84(7): 596 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Ramirez, A. Rosas, J. A. Hernandez-Beriain, J. C. Orengo, P. Saavedra, C. de la Fe, A. Fernandez, and J. B. Poveda Relationship between rheumatoid arthritis and Mycoplasma pneumoniae: a case control study Rheumatology, July 1, 2005; 44(7): 912 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A Voils, M. E Evans, M. T Lane, R. H Schosser, and R. P Rapp Use of Macrolides and Tetracyclines for Chronic Inflammatory Diseases Ann. Pharmacother., January 1, 2005; 39(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M Carty, N Snowden, and A J Silman Should infection still be considered as the most likely triggering factor for rheumatoid arthritis? Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii46 - ii49. [Full Text] [PDF]
|
|
|
|
|
|
E Suresh, I M Morris, and P C Mattingly Use of minocycline in rheumatoid arthritis: a district general hospital experience Ann Rheum Dis, October 1, 2004; 63(10): 1354 - 1355. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. O'Dell Therapeutic Strategies for Rheumatoid Arthritis N. Engl. J. Med., June 17, 2004; 350(25): 2591 - 2602. [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Krupp, L. G. Hyman, R. Grimson, P. K. Coyle, P. Melville, S. Ahnn, R. Dattwyler, and B. Chandler Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial Neurology, June 24, 2003; 60(12): 1923 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Scott and V. Strand The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database Rheumatology, August 1, 2002; 41(8): 899 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Klempner, L. T. Hu, J. Evans, C. H. Schmid, G. M. Johnson, R. P. Trevino, D. Norton, L. Levy, D. Wall, J. McCall, et al. Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease N. Engl. J. Med., July 12, 2001; 345(2): 85 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. I. Kuzin, J. E. Snyder, G. D. Ugine, D. Wu, S. Lee, T. Bushnell Jr, R. A. Insel, F. M. Young, and A. Bottaro Tetracyclines inhibit activated B cell function Int. Immunol., July 1, 2001; 13(7): 921 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Taylor-Robinson and A Keat How can a causal role for small bacteria in chronic inflammatory arthritides be established or refuted? Ann Rheum Dis, March 1, 2001; 60(3): 177 - 185. [Full Text] [PDF]
|
|
|
|
|
|
T. M. Lawson, N. Amos, D. Bulgen, and B. D. Williams Minocycline-induced lupus: clinical features and response to rechallenge Rheumatology, March 1, 2001; 40(3): 329 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bachelez, P. Senet, J. Cadranel, A. Kaoukhov, and L. Dubertret The Use of Tetracyclines for the Treatment of Sarcoidosis Arch Dermatol, January 1, 2001; 137(1): 69 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-T. Labro Interference of Antibacterial Agents with Phagocyte Functions: Immunomodulation or ""Immuno-Fairy Tales""? Clin. Microbiol. Rev., October 1, 2000; 13(4): 615 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Ozog, D. S. Gogstetter, G. Scott, and A. A. Gaspari Minocycline-Induced Hyperpigmentation in Patients With Pemphigus and Pemphigoid Arch Dermatol, September 1, 2000; 136(9): 1133 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. EKLUND and T. SORSA Tetracycline Derivative CMT-3 Inhibits Cytokine Production, Degranulation, and Proliferation in Cultured Mouse and Human Mast Cells Ann. N.Y. Acad. Sci., June 30, 1999; 878(1): 689 - 691. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, J. B. Muhlestein, J. Carlquist, A. Allen, S. Trehan, C. Nielson, S. Hall, J. Brady, M. Egger, B. Horne, et al. Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease and Serological Evidence for Chlamydia pneumoniae Infection : The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study Circulation, March 30, 1999; 99(12): 1540 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Campbell and R. Wernick Update in Rheumatology Ann Intern Med, January 19, 1999; 130(2): 135 - 142. [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Amin, M. G. Attur, G. D. Thakker, P. D. Patel, P. R. Vyas, R. N. Patel, I. R. Patel, and S. B. Abramson A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases PNAS, November 26, 1996; 93(24): 14014 - 14019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Dollery, J. R. McEwan, and A. M. Henney Matrix Metalloproteinases and Cardiovascular Disease Circ. Res., November 1, 1995; 77(5): 863 - 868. [Full Text]
|
|
|
|
 |
|
 Minocycline May Ease Rheumatoid Arthritis Journal Watch Dermatology, March 1, 1995; 1995(301): 13 - 13. [Full Text]
|
|
|
|
 |
|
 MINOCYCLINE MAY EASE RHEUMATOID ARTHRITIS Journal Watch (General), January 31, 1995; 1995(131): 2 - 2. [Full Text]
|
|
Article
